Chimeric Antigen Receptor News and Research

RSS

Eradicating Lingering Cancer Cells Prevents Relapse in B Cell Leukemia

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating with the antibody-drug conjugate (ADC) inotuzumab ozogamicin.

9 Jul 2026

Antibody Drug Conjugate Treatment Destroys Hidden B Cell Leukemia

By using the antibody-drug conjugate (ADC) inotuzumab ozogamicin to treat B-cell acute lymphoblastic leukemia (ALL) patients, researchers at The University of Texas MD Anderson Cancer Center were able to eliminate measurable residual disease (MRD), a crucial step in enhancing long-term survival outcomes.

8 Jul 2026

Cancer Cells Hijack Macrophage Metabolism to Create an Immunosuppressive Tumor Microenvironment

Tumor-associated macrophages (TAMs) are among the most abundant immune cells in the tumor microenvironment. However, instead of attacking cancer cells, they are typically co-opted to support tumor growth, metastasis, and therapeutic resistance.

2 Jul 2026

New Progenitor Cell Platform Offers Scalable Source for Immunotherapy

In a paper published in Cell, a USC Stem Cell-led team reports a new way of generating a renewable and expandable supply of the progenitor cells that give rise to macrophages.

22 Jun 2026

New Pipeline Sharpens Single-Cell Profiling of CAR Immune Therapies

CERTOMICS is a Nextflow-based computational pipeline designed to identify and profile CAR-engineered immune cells using single-cell multiomics data. By integrating gene expression, immune receptor profiling, protein markers, CAR-aware references, and CAR-specific quality control, it supports more standardized analysis of adoptive cellular immunotherapies.

29 Apr 2026

Novel Immunotherapy Disrupts the Protective Tumor Microenvironment Ecosystem

Chimeric antigen receptor T-cell therapy - CAR T for short - has been a major advance in treating blood cancers like leukemia and lymphoma. But the immunotherapy has struggled against solid tumors for two main reasons: tumor cells often don't share one consistent surface target, and many solid tumors are protected by a dense network of scar tissue and immune-suppressive cells that blocks T cells.

31 Mar 2026

Macrophages Offer a Safer Alternative to CAR-T Therapies with Lower Toxicity

A new study from researchers at Wake Forest University School of Medicine has identified a promising strategy to treat brain metastases, one of the most challenging and deadly complications of lung cancer.

3 Mar 2026

Engineered CD4 CAR T Cells Reduce Amyloid Plaques in Alzheimer’s

Findings suggest engineered CD4+ T cells can modify Alzheimer's pathology and improve CNS immune responses, highlighting a novel therapeutic approach.

19 Feb 2026

New Genetic Rules Guide Killer T Cell Fate

A multi-institutional study led by researchers at UNC Lineberger Comprehensive Cancer Center, the Salk Institute for Biological Studies, and UC San Diego has uncovered new genetic rules that determine how powerful immune cells-known as CD8 killer T cells-choose between becoming long-lasting, protective defenders or slipping into exhausted, dysfunctional states.

6 Feb 2026

Elusive Kinase State Explains How Cells Achieve Efficient Signaling

Scientists at St. Jude Children's Research Hospital have characterized a hidden intermediate state at the center of Src kinase function. This hidden state allows the kinase to repeatedly modify its target, without needing to release

19 Dec 2025

New Multi-Target CAR-T Cells Eradicate Glioblastoma in Preclinical Models

With a five-year survival rate of less than 5%, glioblastoma is one of the most aggressive types of brain cancer.

21 Nov 2025

Cracking the Code of T Cell Expansion Inside Tumors

The ability of immune cells-particularly CD8+ T cells-to launch a rapid burst of proliferation inside tumors is key to the success of modern day cancer immunotherapies.

22 Oct 2025

GlyTR Therapeutics Unveils Groundbreaking Glycan-Targeting Cancer Immunotherapy

GlyTR Therapeutics, a biotech company pioneering development of glycan-targeting cancer immunotherapies, announced the publication of its foundational technology in the journal, Cell.

14 Oct 2025

Automated 15-minute, Aseptic Micro-Sampling of T Cells

Auto-CeSS is an automated system for aseptic 30 μL sample collection, enhancing process monitoring and reducing contamination in cell therapy manufacturing.

13 Aug 2025

Engineered Macrophages Enable CAR T Cells to Overcome Glioblastoma Barriers

A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and Luigi Naldini, has unveiled a powerful strategy to rejuvenate the effectiveness of chimeric antigen receptor (CAR) T cell therapy against glioblastoma, one of the most lethal and treatment-resistant brain tumors.

4 Jul 2025